Sign In

Andreas Scherer

President and CEO @ Golden Helix Inc.

Andreas Scherer is the President and CEO of Golden Helix Inc., a position he has held since April 2013. He is based in Bozeman, Montana, and has a strong focus on building and refining companies, particularly in the fields of pharmacogenetics and health innovation. Under his leadership, Golden Helix has celebrated significant milestones, including receiving an NIH SBIR grant and ISO 13485:2016 certification.12

In addition to his role at Golden Helix, Scherer is also the President and CEO of Salto Partners Inc., a position he has maintained since January 2012. His expertise includes digital transformation and innovation technology, and he is recognized as a motivational speaker.13 Scherer is fluent in both German and English, showcasing his bilingual proficiency.1

His professional journey emphasizes a disciplined approach to managing organizational resources to meet business goals effectively.1

Highlights

Jun 13 · linkedin

Exciting news! Golden Helix has been recognized by Life Science Review as one of the top NGS Solutions Companies, and it is featured in their cover story. The article highlights our work in cancer and rare diseases, along with our new pharmacogenomics capabilities. We are also thrilled to share the latest update on receiving the CE mark just a few weeks ago. Check out the full feature here: https://lnkd.in/dVE7J3xN

#goldenhelix #NGS #PrecisionMedicine #PrecisionOncology #rarediseases #PGx #CE #IVDR

May 31 · linkedin

Just made it to the wonderful city of Berlin. It's always great to come back and see the amazing developments that take place here in town.

The entire Goldenhelix team is excited to exhibit our solutions at this event. Please come to booth #428 to visit us. There are every day in-booth demos on topics such as IVDR/VarSeq DX, Cancer Analytics, Clinical Reporting of germline variants and our latest support for PGx workflows.

Especially interesting is our Corporate Satellite talk: "Golden Helix, Inc. – A Clinical Interpretation Solution for Next-Generation Sequencing Labs" 🗓️ Monday, June 3 🕛 12:00 – 13:00 📍 Room: New York 1 Presented by: Andreas Scherer, PhD, President and CEO Nathan Fortier, PhD, Director of Research Jennifer Dankoff, PhD, Field Application Scientist Guest Speakers: Chung-Ting (Tina) Han, PhD, Director of Applications & Business Development, Twist Bioscience David Stucki, Field Application Support Manager, PacBio We will talk about our high-quality variant analysis and interpretation capabilities that can efficiently implement ACMG and AMP guidelines for variant interpretation. We will touch on directly calling CNVs in target regions, exomes, and whole genomes, and utilizing repeatable clinical interpretation workflows. We will also introduce our pharmacogenomics solution, VSPGx, based on CPIC guidelines and share some of its exciting capabilities in detail.

#ESHG2024 #GoldenHelix #NextGenerationSequencing #VarSeq #VarSeqDX #Genomics #Pharmacogenomics #VSPGx #ACMG #AMP #CPIC #Genetics

Related Questions

What are Andreas Scherer's key achievements at Golden Helix Inc?
How did Andreas Scherer transition from Salto Partners Inc. to Golden Helix Inc?
What are some notable projects Andreas Scherer has led at Golden Helix Inc?
What is Andreas Scherer's background before becoming CEO at Golden Helix Inc?
How has Andreas Scherer influenced the field of pharmacogenetics at Golden Helix Inc?
Andreas Scherer
Andreas Scherer, photo 1
Andreas Scherer, photo 2
Add to my network

Location

Bozeman, Montana, United States